Aspirin Use in Sturge-Weber Syndrome

Journal of Child Neurology
28, 213-218
DOI: 10.1177/0883073812463607

Citation Report

#	Article	IF	Citations
1	Sturgeâ€“Weber Syndrome. , 0, , 200-207.		0
3	Angiome cutanÃ© rÃ©vÃ©lant un syndrome neuro-cutanÃ© chez lâ€™enfant. Archives De Pediatrie, 2013, 20, H197-H199.	0.4	0
4	Sturge-Weber Syndrome. Current Treatment Options in Neurology, 2013, 15, 607-617.	0.7	41
5	Patterns of vascular birthmarks: questions and clues. British Journal of Dermatology, 2014, 171, 693-694.	1.4	2
6	The challenging task of screening and monitoring tuberculosis infection in candidates for biological therapies. British Journal of Dermatology, 2014, 171, 694-695.	1.4	0
7	New vascular classification of portâ€wine stains: improving prediction of Sturgeâ€“Weber risk. British Journal of Dermatology, 2014, 171, 861-867.	1.4	146
8	An overview of current and future treatment options for Sturgeâ€“Weber syndrome. Expert Opinion on Orphan Drugs, 2014, 2, 1015-1025.	0.5	1
9	Preliminary reliability and validity of a battery for assessing functional skills in children with Sturge-Weber syndrome. Child's Nervous System, 2014, 30, 2027-2036.	0.6	7
10	Sturge-Weber Syndrome. Advances in Neonatal Care, 2014, 14, 96-102.	0.5	2
12	Aspirin Therapy in Venous Malformation: A Retrospective Cohort Study of Benefits, Side Effects, and Patient Experiences. Pediatric Dermatology, 2014, 31, 556-560.	0.5	33
13	Stimulant Use in Patients With Sturge-Weber Syndrome: Safety and Efficacy. Pediatric Neurology, 2014, 51, 675-680.	1.0	18
14	Sturgeâ€“Weber Syndrome. , 2015, , 945-953.		0
15	Sturgeâ€“Weber syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2015, 132, 157-168.	1.0	67
16	Current Therapeutic Options in Sturge-Weber Syndrome. Seminars in Pediatric Neurology, 2015, 22, 295-301.	1.0	86
17	Mosaic Neurocutaneous Disorders and Their Causes. Seminars in Pediatric Neurology, 2015, 22, 207-233.	1.0	81
18	Visual outcome in Sturgeâ€“Weber syndrome: a systematic review and Dutch multicentre cohort. Acta Ophthalmologica, 2016, 94, 638-645.	0.6	15
20	Correction of Facial Deformity in Sturgeâ€“Weber Syndrome. Plastic and Reconstructive Surgery - Global Open, 2016, 4, e843.	0.3	13
21	Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review. Current Neurology and Neuroscience Reports, 2016, 16, 19.	2.0	5

#	Article	IF	Citations
22	Cutaneous and ocular manifestations of neurocutaneous syndromes. Clinics in Dermatology, 2016, 34, 183-204.	0.8	23
23	Leveraging a Sturge-Weber Gene Discovery: An Agenda for FutureÂResearch. Pediatric Neurology, 2016, 58, 12-24.	1.0	19
24	Sturgeâ€“Weber Syndrome. Journal of Pediatric Epilepsy, 2016, 05, 082-088.	0.1	3
25	Intellectual and adaptive functioning in Sturge-Weber Syndrome. Child Neuropsychology, 2016, 22, 635-648.	0.8	17
26	AnÃ¡lisis del sÃndrome de Sturge-Weber: estudio retrospectivo de mÃºltiples variables asociadas. NeurologÃa, 2017, 32, 363-370.	0.3	19
27	SÃndrome de Sturge-Weber: revisiÃ³n. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 407-417.	0.2	53
28	Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy. Epilepsy Research, 2017, 131, 15-27.	0.8	37
29	Sturge-Weber Syndrome: A Review. Actas Dermo-sifiliogrÃ¡ficas, 2017, 108, 407-417.	0.2	11
30	Analysis of Sturgeâ€“Weber syndrome: A retrospective study of multiple associated variables. NeurologÃa (English Edition), 2017, 32, 363-370.	0.2	7
31	Neurocutaneous Syndromes and Associated CNS Tumors. Pediatric Oncology, 2017, , 237-271.	0.5	0
32	Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturgeâ€“Weber Syndrome. Frontiers in Neurology, 2017, 8, 87.	1.1	38
33	Brush sign in Sturge-Weber syndrome. Pediatric Radiology, 2018, 48, 895-896.	1.1	5
35	A Multidisciplinary Consensus for Clinical Care and Research Needs for Sturge-Weber Syndrome. Pediatric Neurology, 2018, 84, 11-20.	1.0	42
36	Screening for Sturgeâ€“Weber syndrome: A stateâ€ofâ€theâ€art review. Pediatric Dermatology, 2018, 35, 30-42.	0.5	30
37	Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. Neuropathology and Applied Neurobiology, 2018, 44, 91-111.	1.8	186
38	Yield of Emergent Neuroimaging in Patients With Sturge-Weber Syndrome Presenting With Acute Neurologic Symptoms. Journal of Child Neurology, 2018, 34, 088307381880163.	0.7	2
39	Evidence-Based Management of Head and Neck Vascular Anomalies. , 2018, , .		1
40	Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nature Reviews Neurology, 2019, 15, 459-472.	4.9	463

#	Article	IF	Citations
41	Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. Journal of Neuroinflammation, 2019, 16, 197.	3.1	79
42	Neurological Complications of Sturge-Weber Syndrome: Current Status and Unmet Needs. Pediatric Neurology, 2019, 98, 31-38.	1.0	17
43	Preventive treatment with oral sirolimus and aspirin in a newborn with severe Sturgeâ€Weber syndrome. Pediatric Dermatology, 2019, 36, 524-527.	0.5	15
44	Aspirin in childhood acute ischemic stroke: The evidence for treatment and efficacy testing. Pediatric Blood and Cancer, 2019, 66, e27665.	0.8	7
45	The COX-2/prostanoid signaling cascades in seizure disorders. Expert Opinion on Therapeutic Targets, 2019, 23, 1-13.	1.5	46
46	Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset. Pediatric Neurology, 2019, 90, 8-12.	1.0	33
47	Mosaic abnormalities of the skin: review and guidelines from the European Reference Network for rare skin diseases. British Journal of Dermatology, 2020, 182, 552-563.	1.4	45
48	Atypical Intracerebral Developmental Venous Anomalies in Sturge-Weber Syndrome: A Case Series and Review of Literature. Pediatric Neurology, 2020, 104, 54-61.	1.0	4
49	The role of inflammation in epileptogenesis. Acta Epileptologica, 2020, 2, .	0.4	24
50	Vascular Anomalies. , 2020, , .		3
51	Sturge-Weber Syndrome and Haematuria: a Case Report of an Unusual Presentation. SN Comprehensive Clinical Medicine, 2020, 2, 2957-2961.	0.3	0
52	Altered plasma prostaglandin E2 levels in epilepsy and in response to antiepileptic drug monotherapy. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 153, 102056.	1.0	5
53	Therapeutic role of targeting mTOR signaling and neuroinflammation in epilepsy. Epilepsy Research, 2020, 161, 106282.	0.8	48
54	Impact of Stress on Epilepsy: Focus on Neuroinflammationâ€"A Mini Review. International Journal of Molecular Sciences, 2021, 22, 4061.	1.8	18
55	Multicenter Research Data of Epilepsy Management in Patients With Sturge-Weber Syndrome. Pediatric Neurology, 2021, 119, 3-10.	1.0	10
56	Neurological presentations and cognitive outcome in Sturge-Weber syndrome. European Journal of Paediatric Neurology, 2021, 34, 21-32.	0.7	13
57	Sturge-Weber syndrome type 3 manifesting as â€˜Status migrainosusâ€™. BMJ Case Reports, 2016, 2016, bcr2016216842.	0.2	5
58	Neurocutaneous Disorders. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 96-129.	0.4	19

#	Article	IF	Citations
59	Epileptogenesis in neurocutaneous disorders with focus in Sturge Weber syndrome. F1000Research, 2016, 5, 370.	0.8	28
60	Encephalotrigeminal Angiomatosis: A Review with Emphasis on Head and Neck Manifestations. Neurographics, 2021, 11, 166-174.	0.0	0
61	Neurokutane Syndrome. , 2014, , 1670-1680.		0
63	Vascular Anomalies. , 2016, , 173-189.		0
64	Developmental malformations. , 2016, , 107-191.		0
65	Sturge-Weber Syndrome with Bipolar Presentation: A Case Report. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, 11, .	0.1	0
67	Sturge-Weber syndrome Case report. Forum Ortodontyczne, 2018, 14, 51-57.	0.0	0
68	Neurokutane Syndrome bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-24.	0.0	0
70	Severe Sturge-Weber syndrome in a 9-year-old boy: a great challenge. International Journal of Ophthalmology, 2020, 13, 1340-1342.	0.5	0
71	Neurosurgical Considerations of Neurocutaneous Syndromes. Neurosurgery Clinics of North America, 2022, 33, 81-89.	0.8	2
72	Neurokutane Syndrome. Springer Reference Medizin, 2020, , 2477-2500.	0.0	0
74	Sturgeâ€“Weber syndrome. , 2020, , 213-223.		1
75	Capillary Malformations and Associated Syndromes. , 2020, , 105-119.		0
76	Focal venous hypertension as a pathophysiologic mechanism for tissue hypertrophy, port-wine stains, the Sturge-Weber syndrome, and related disorders: proof of concept with novel hypothesis for underlying etiological cause (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2013, 111, 180-215.	1.4	24
77	Brain Vascular Malformation Consortium: Overview, Progress and Future Directions. The Journal of Rare Disorders, 2013, 1, 5.	1.5	21
78	The Interconnected Mechanisms of Oxidative Stress and Neuroinflammation in Epilepsy. Antioxidants, 2022, 11, 157.	2.2	36
81	The Clinical Characteristics of New-Onset Epilepsy in the Elderly and Risk Factors for Treatment Outcomes of Antiseizure Medications. Frontiers in Neurology, 2022, 13, 819889.	1.1	2
82	Characteristics, surgical outcomes, and influential factors of epilepsy in Sturge-Weber syndrome. Brain, 2022, 145, 3431-3443.	3.7	12

#	Article	IF	Citations
83	Early MRI diagnosis of Sturge Weber Syndrome type 1 in infants. European Journal of Paediatric Neurology, 2022, 38, 66-72.	0.7	4
84	Focal lesionectomy as surgical treatment of epilepsy in patients with Sturge-Weber syndrome: a case-based systematic review and meta-analysis. Neurosurgical Focus, 2022, 52, E4.	1.0	2
85	Multi-Center Assessment of Sturge-Weber Syndrome: A Retrospective Study of Variations in Care and Use of Natural History Data. Pediatric Neurology, 2022, , .	1.0	2
86	Low-Dose Acetylsalicylic Acid Treatment in Non-Skull-Base Meningiomas: Impact on Tumor Proliferation and Seizure Burden. Cancers, 2022, 14, 4285.	1.7	1
87	Port-wine Birthmarks: Update on Diagnosis, Risk Assessment for Sturge-Weber Syndrome, and Management. Pediatrics in Review, 2022, 43, 507-516.	0.2	8
88	Updates on Sturge-Weber Syndrome. Stroke, 2022, 53, 3769-3779.	1.0	10
89	Deep Venous Remodeling in Unilateral Sturge-Weber Syndrome: Robust Hemispheric Differences and Clinical Correlates. Pediatric Neurology, 2023, 139, 49-58.	1.0	1
90	Systemic inflammation as a biomarker of seizure propensity and a target for treatment to reduce seizure propensity. Epilepsia Open, 2023, 8, 221-234.	1.3	1
91	Reduction of seizures and inflammatory markers by betamethasone in a kindling seizure model. Steroids, 2023, 193, 109202.	0.8	1
92	Management of Pediatric Patient with Non-NF Phakomatosis. , 2023, , 213-229.		0